[{"address1": "4224 Campus Point Court", "address2": "Suite 210", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 202 6300", "website": "https://www.regulusrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.", "fullTimeEmployees": 32, "companyOfficers": [{"maxAge": 1, "name": "Mr. Joseph P. Hagan M.B.A.", "age": 55, "title": "CEO & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 958232, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Crispina  Calsada CPA", "age": 54, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 579300, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher Ray Aker J.D.", "age": 63, "title": "Senior VP, General Counsel & Corporate Secretary", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 575942, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Preston S. Klassen M.D., M.H.S.", "age": 55, "title": "President, Head of Research & Development and Director", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel J. Penksa", "age": 38, "title": "VP of Finance & Controller", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Claire Susan Padgett M.S., M.T., Ph.D.", "title": "Senior Vice President of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rekha  Garg M.D., M.S.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edmund  Lee Ph.D.", "title": "Vice President of Translational Medicine", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 3, "compensationRisk": 9, "shareHolderRightsRisk": 6, "overallRisk": 6, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.21, "open": 1.21, "dayLow": 1.21, "dayHigh": 1.27, "regularMarketPreviousClose": 1.21, "regularMarketOpen": 1.21, "regularMarketDayLow": 1.21, "regularMarketDayHigh": 1.27, "beta": 1.628, "forwardPE": -1.0877193, "volume": 278990, "regularMarketVolume": 278990, "averageVolume": 359268, "averageVolume10days": 361650, "averageDailyVolume10Day": 361650, "bid": 0.8928, "ask": 1.58, "bidSize": 200, "askSize": 200, "marketCap": 81220128, "fiftyTwoWeekLow": 1.16, "fiftyTwoWeekHigh": 3.79, "fiftyDayAverage": 1.4896, "twoHundredDayAverage": 1.77475, "currency": "USD", "enterpriseValue": -4843834, "floatShares": 42412647, "sharesOutstanding": 65500100, "sharesShort": 1695685, "sharesShortPriorMonth": 1401340, "sharesShortPreviousMonthDate": 1732838400, "dateShortInterest": 1735603200, "sharesPercentSharesOut": 0.025899999, "heldPercentInsiders": 0.02343, "heldPercentInstitutions": 0.88307, "shortRatio": 6.17, "shortPercentOfFloat": 0.032899998, "impliedSharesOutstanding": 65500100, "bookValue": 1.325, "priceToBook": 0.935849, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -41628000, "trailingEps": -1.02, "forwardEps": -1.21, "lastSplitFactor": "1:10", "lastSplitDate": 1656460800, "enterpriseToEbitda": 0.109, "52WeekChange": -0.015873015, "SandP52WeekChange": 0.23809385, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "RGLS", "underlyingSymbol": "RGLS", "shortName": "Regulus Therapeutics Inc.", "longName": "Regulus Therapeutics Inc.", "firstTradeDateEpochUtc": 1349789400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "cd43addf-be3b-3da4-8113-29f5cb221300", "messageBoardId": "finmb_36742485", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.24, "targetHighPrice": 28.0, "targetLowPrice": 3.0, "targetMeanPrice": 10.33333, "targetMedianPrice": 7.5, "recommendationKey": "none", "numberOfAnalystOpinions": 6, "totalCash": 87309000, "totalCashPerShare": 1.333, "ebitda": -44258000, "totalDebt": 1240000, "quickRatio": 13.469, "currentRatio": 14.145, "debtToEquity": 1.428, "returnOnAssets": -0.42387, "returnOnEquity": -0.72356004, "grossProfits": -22623000, "freeCashflow": -21584124, "operatingCashflow": -35953000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-25"}]